Alphatec Holdings stock
ATECNASDAQAlphatec Holdings, Inc., HealthcareISIN US02081G2012
34Score 34 out of 100, Weak
Price and trend
27 / 100
Price history
−66% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 31% below it.
Since March 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Sharply down: the price has fallen very quickly lately (RSI 26).
The price is 69% below its 52-week high. Largest decline in 20 years: 99% (April 2010 to February 2019).
Chart figures for advanced users
- SMA 50$9.80
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$10.16
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)26
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$6.99
- The lowest closing price of the last twelve months.
- Resistance$22.68
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Alphatec Holdings, Inc. belongs to the Medical (Devices) industry (United States) and, with a market value of $1.1B, is number 55 of 90 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $764.16M (up 25% year on year) and a loss of $143.36M.
- For fiscal 2026, analysts expect on average revenue of $864.84M (up 13.2%) and adjusted earnings per share of $0.29.
Show more
- MEQIRI Score 34 out of 100 (Weak): rank 643 of 714 in Healthcare, median 53.
- Our model puts fair value at $14.33, with the price 49% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 39.5% a year since 2020, Medical (Devices) median 13.8%.Growth 70
Weaknesses
- High debtDebt 27.88 times equity (latest quarter), Medical (Devices) median 0.47.Stability 26
- DilutionShare count up 124% since 2020.Capital allocation 18
- Loss-makingLoss of $86.89M over the last 12 months.Fundamentals 17
Its standout strengths are growth and valuation, while capital allocation and fundamentals hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- price far below its 52-week high
- weak fundamentals
- high price swings
What lowers it
- price not overheated over the past year
Valuation
Valuation signal
Possible value trapClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $9.56 and expensive above $28.67 (uncertainty very high, based on the price swings of the past year).
Calculated with a cost of equity of 10%. At 11% the fair value would be $12.33, at 9% it would be $17.12.
Possible value trap: looks cheap, but score below 50, high risk, weak balance sheet.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 15.3% on the twelve months before. Revenue has grown strongly since 2006, at around 13% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 70%, operating −11%, net −19%. Last 12 months: net −10%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 23 Feb 2027in 103 days
- Last reported
- 29 Oct 2026EPS reported $0.09 (expected $0.10)below expectations
Analyst estimates
Analysts have cut their 2026 earnings estimate by 9.9% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- $0.29−9.9%
- Revenue
- $864.84M−2.0%
- Earnings per share
- $0.56−7.6%
- Revenue
- $979.51M−3.5%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: −5.7%2026 adjusted EBITDA guidance raised to about $140 million (before: $134 million), with revenue guidance of about $882 million reaffirmed.
“Given our growth outlook, sustained improvement in gross margins, and ongoing operating discipline, we are raising our adjusted EBITDA guidance to approximately $140 million, representing a 16% margin, up from our prior outlook of $134 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 4 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
2 insiders bought on the open market in the last 6 months, $1.26M in total. 2 insiders sold, $127,282 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Not counted: one purchase under a fixed plan (compensation, savings plan or a pre-arranged Rule 10b5-1 trading plan).
- Valentine KeithPurchase
10 Nov 2026, Board
- Shares
- 35,000
- Price
- $6.93
- Value
- $242,550
- Demski David MPlan purchase
30 Oct 2026, Board
- Shares
- 60,000
- Price
- $6.81
- Value
- $408,600
- Miles PatrickPurchase
10 Sept 2026, CEO
- Shares
- 115,000
- Price
- $8.81
- Value
- $1.01M
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Alphatec Holdings
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 34
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- NovocureNVCR $1.4B30
- PROCEPT BioRoboticsPRCT $1.34B41
- Tandem Diabetes CareTNDM $1.31B45
- Integra LifeSciences HoldingsIART $1.15B50
- SI-BONESIBN $1.13B47
- IRadimedIRMD $1.11B77
- CeriBellCBLL $1.08B49
- AdaptHealthAHCO $1.06B33
ETFs that hold Alphatec Holdings
Held by 11 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Ageing Population UCITS ETF2B77 | 0.09% | 0.40% | €807M |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.04% | 0.30% | €185.82M |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.03% | 0.30% | €2.17B |
Show 5 more
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.03% | 0.30% | €4.22B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.01% | 0.43% | €2.48B |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.01% | 0.35% | €8.19B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.00% | 0.35% | €434.1M |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.00% | 0.30% | €944.34M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 May 2007)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.